Logo image of RNTX

REIN THERAPEUTICS INC (RNTX) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:RNTX - US00887A2042 - Common Stock

1.24 USD
-0.08 (-6.06%)
Last: 12/26/2025, 8:14:22 PM
1.1979 USD
-0.04 (-3.4%)
After Hours: 12/26/2025, 8:14:22 PM
Fundamental Rating

2

Overall RNTX gets a fundamental rating of 2 out of 10. We evaluated RNTX against 530 industry peers in the Biotechnology industry. The financial health of RNTX is average, but there are quite some concerns on its profitability. RNTX has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year RNTX has reported negative net income.
RNTX had a negative operating cash flow in the past year.
RNTX had negative earnings in each of the past 5 years.
RNTX had a negative operating cash flow in each of the past 5 years.
RNTX Yearly Net Income VS EBIT VS OCF VS FCFRNTX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M

1.2 Ratios

With a Return On Assets value of -109.64%, RNTX is not doing good in the industry: 78.11% of the companies in the same industry are doing better.
Looking at the Return On Equity, with a value of -127.48%, RNTX is doing worse than 61.51% of the companies in the same industry.
Industry RankSector Rank
ROA -109.64%
ROE -127.48%
ROIC N/A
ROA(3y)-80.04%
ROA(5y)-84.72%
ROE(3y)-92.8%
ROE(5y)-102.4%
ROIC(3y)N/A
ROIC(5y)N/A
RNTX Yearly ROA, ROE, ROICRNTX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100 -200 -300

1.3 Margins

RNTX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
RNTX Yearly Profit, Operating, Gross MarginsRNTX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024

More info and screens

4

2. Health

2.1 Basic Checks

The number of shares outstanding for RNTX has been increased compared to 1 year ago.
The number of shares outstanding for RNTX has been increased compared to 5 years ago.
There is no outstanding debt for RNTX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
RNTX Yearly Shares OutstandingRNTX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M
RNTX Yearly Total Debt VS Total AssetsRNTX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

2.2 Solvency

RNTX has an Altman-Z score of -8.50. This is a bad value and indicates that RNTX is not financially healthy and even has some risk of bankruptcy.
RNTX has a Altman-Z score of -8.50. This is in the lower half of the industry: RNTX underperforms 69.81% of its industry peers.
RNTX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -8.5
ROIC/WACCN/A
WACCN/A
RNTX Yearly LT Debt VS Equity VS FCFRNTX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M 60M 80M

2.3 Liquidity

RNTX has a Current Ratio of 0.90. This is a bad value and indicates that RNTX is not financially healthy enough and could expect problems in meeting its short term obligations.
RNTX's Current ratio of 0.90 is on the low side compared to the rest of the industry. RNTX is outperformed by 88.68% of its industry peers.
A Quick Ratio of 0.90 indicates that RNTX may have some problems paying its short term obligations.
With a Quick ratio value of 0.90, RNTX is not doing good in the industry: 88.11% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 0.9
Quick Ratio 0.9
RNTX Yearly Current Assets VS Current LiabilitesRNTX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M

More info and screens

1

3. Growth

3.1 Past

RNTX shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 5.77%.
EPS 1Y (TTM)5.77%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%22.22%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 20.55% on average over the next years. This is a very strong growth
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y74.23%
EPS Next 2Y33.47%
EPS Next 3Y20.55%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
RNTX Yearly Revenue VS EstimatesRNTX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2030 2031 2032 50M 100M 150M 200M 250M
RNTX Yearly EPS VS EstimatesRNTX Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 -10 -20 -30 -40

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for RNTX. In the last year negative earnings were reported.
Also next year RNTX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
RNTX Price Earnings VS Forward Price EarningsRNTX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
RNTX Per share dataRNTX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 -2

4.3 Compensation for Growth

A more expensive valuation may be justified as RNTX's earnings are expected to grow with 20.55% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y33.47%
EPS Next 3Y20.55%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for RNTX!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

REIN THERAPEUTICS INC

NASDAQ:RNTX (12/26/2025, 8:14:22 PM)

After market: 1.1979 -0.04 (-3.4%)

1.24

-0.08 (-6.06%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-14 2025-11-14/bmo
Earnings (Next)04-06 2026-04-06/amc
Inst Owners32.69%
Inst Owner ChangeN/A
Ins Owners0.08%
Ins Owner ChangeN/A
Market Cap32.60M
Revenue(TTM)N/A
Net Income(TTM)-58.88M
Analysts82.5
Price Target8.16 (558.06%)
Short Float %1.62%
Short Ratio0.37
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-5.28%
Min EPS beat(2)-24.78%
Max EPS beat(2)14.22%
EPS beat(4)1
Avg EPS beat(4)-365.57%
Min EPS beat(4)-1451.7%
Max EPS beat(4)14.22%
EPS beat(8)2
Avg EPS beat(8)-343.28%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)14.29%
EPS NQ rev (1m)2.27%
EPS NQ rev (3m)-7.5%
EPS NY rev (1m)1.04%
EPS NY rev (3m)-3.8%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.71
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-2.94
EYN/A
EPS(NY)-0.83
Fwd EYN/A
FCF(TTM)-0.8
FCFYN/A
OCF(TTM)-0.8
OCFYN/A
SpS0
BVpS1.76
TBVpS-0.09
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -109.64%
ROE -127.48%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-80.04%
ROA(5y)-84.72%
ROE(3y)-92.8%
ROE(5y)-102.4%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.9
Quick Ratio 0.9
Altman-Z -8.5
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)5.77%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%22.22%
EPS Next Y74.23%
EPS Next 2Y33.47%
EPS Next 3Y20.55%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y19.75%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-51.5%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-51.5%
OCF growth 3YN/A
OCF growth 5YN/A

REIN THERAPEUTICS INC / RNTX FAQ

What is the fundamental rating for RNTX stock?

ChartMill assigns a fundamental rating of 2 / 10 to RNTX.


What is the valuation status for RNTX stock?

ChartMill assigns a valuation rating of 1 / 10 to REIN THERAPEUTICS INC (RNTX). This can be considered as Overvalued.


How profitable is REIN THERAPEUTICS INC (RNTX) stock?

REIN THERAPEUTICS INC (RNTX) has a profitability rating of 0 / 10.


Can you provide the expected EPS growth for RNTX stock?

The Earnings per Share (EPS) of REIN THERAPEUTICS INC (RNTX) is expected to grow by 74.23% in the next year.